Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-01: AZD5335 versus mirvetuximab soravtansine or investigator's choice chemotherapy in platinum-resistant FRα-positive recurrent ovarian cancer
CTR20261196Phase 3Active
- Sponsor
- AstraZeneca
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AZD5335 in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started May 2026; status: active.
02
Drugs
AZD5335
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20261196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261196.